Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Iovance Biotherapeutics (IOVA) over the last 8 years, with Q3 2025 value amounting to $9.3 million.

  • Iovance Biotherapeutics' Other Non-Current Assets changed N/A to $9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 million, marking a year-over-year change of. This contributed to the annual value of $6.4 million for FY2024, which is 9042.75% down from last year.
  • Iovance Biotherapeutics' Other Non-Current Assets amounted to $9.3 million in Q3 2025.
  • Over the past 5 years, Iovance Biotherapeutics' Other Non-Current Assets peaked at $66.4 million during Q2 2023, and registered a low of $5.8 million during Q1 2025.
  • Its 3-year average for Other Non-Current Assets is $27.1 million, with a median of $9.3 million in 2025.
  • Within the past 5 years, the most significant YoY rise in Iovance Biotherapeutics' Other Non-Current Assets was 0.0% (2024), while the steepest drop was 9042.75% (2024).
  • Over the past 3 years, Iovance Biotherapeutics' Other Non-Current Assets (Quarter) stood at $66.4 million in 2023, then crashed by 90.43% to $6.4 million in 2024, then surged by 45.79% to $9.3 million in 2025.
  • Its Other Non-Current Assets stands at $9.3 million for Q3 2025, versus $10.3 million for Q2 2025 and $5.8 million for Q1 2025.